-
Selumetinib granted orphan status for NF1 treatment
-
Immunotherapy trial for prostate cancer patients
-
Activated platelets can promote tumor cell invasion into healthy tissue
-
Focusing on function to mine cancer genome data
-
Phase I clinical trial will test multi-targeted immunotherapy in common childhood cancer
-
#NCISingleCell2018 welcomes Rafael Casellas at 3:30pmET for his talk on nuclear architecture and transcription https://t.co/iVmZ94IFsR
-
Dr. Efsun Arda, one of our newest @NIH Stadtman Investigators, will discuss #pancreas development in her 3:00pmET l… https://t.co/BoL1WNzzNZ
-
FDA grants orphan drug status to selumetinib for #NF1 treatment. Read more at: https://t.co/KgVKKTrdKb https://t.co/0f0PNEwB2F
-
We return back from our poster session to hear Peter Fraser @fsubio talk at 2:30pmET titled "Chromosome and #Genome… https://t.co/kVGyFM2DY9
-
RT @NCItreatment: Read @theNCI's Cancer Currents Blog on NCI's Patient-Derived Models Repository, "NCI Expands Repository of Cancer R… https://t.co/ETvQwyHLxT
-
At 12pmET, our own Xin Wei Wang will present on #livertumor and #singlecell analysis at #NCISingleCell2018 https://t.co/8c3uQCFxuA
-
#NCISingleCell2018 Coming up at 11:30amET, Calvin Kuo @StanfordMed will present "Cancer Development" https://t.co/NJjOCu4omT
